Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



1 Big Catalyst for Amarin Investors... Maybe

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Amarin (NASDAQ: AMRN  ) investors, it's almost that time again. The FDA's Orange Book should be updated later this week and it may contain news regarding Vascepa. Whether the NCE decision is finally put to rest or if yet another delay is in the cards is anyone's guess. However, there are plenty of other aspects to Amarin's business that investors all need to pay attention to. In this video, health-care analyst Max Macaluso runs through the main issues investors need to watch in the coming weeks.

Can Amarin beat the odds?

Small biotech companies usually crash and burn when it comes to launching drugs, but can Amarin prove the doubters wrong with its new lipid-lowering drug? In our new premium research report, The Motley Fool's top biotech analyst offers an in-depth look at this drugmaker's upcoming opportunities, along with reasons to buy and sell this stock today. To find out more -- and receive a full year of free bonus updates as news develops -- simply click here now to claim your copy.

Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 12, 2013, at 9:09 PM, NoPanicBill wrote:

    Where you just bored and wanted to do a video performance. Why not talk about the important upcoming catalyst? There is the sNDA on the Anchor study on 2/28. There is also something more important that you could have reported on. It's name is The Reduce-It Study. There is an announcement, which is the First on this very important study, also do on 2/28. These two pieces of AMRN are what is most important to n editors. Fools would like to hear DD on this, not NCE that is near meaningless by now, because of the increasing portfolio of patents. These items are much more important. Please do some informing on AMRN. Thank You.

  • Report this Comment On February 13, 2013, at 9:59 AM, yazzbro wrote:

    Most of these AMRN articles and videos are to see how many clicks they can get. This story has absolutely no new information from the last time they ran an AMRN story or the several prior to that. Like I said it's all about getting people to come on the site so they can make money on advertising.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2251425, ~/Articles/ArticleHandler.aspx, 9/26/2016 11:59:42 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,118.11 -143.34 -0.78%
S&P 500 2,150.32 -14.37 -0.66%
NASD 5,265.73 -40.02 -0.75%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 11:43 AM
AMRN $3.06 Up +0.12 +4.08%
Amarin CAPS Rating: ****